Citigroup Downgraded Indivior (INVVY)’s Rating From Buy To Neutral.

May 16, 2018 - By Madeline Delgado

Indivior PLC (OTCMKTS:INVVY) Corporate Logo

Citigroup Cut Indivior (INVVY)’s Rating to Neutral.

On Tuesday morning Citigroup changed the $4.60B MC company’s rating. analysts has decreased it to Neutral from Buy.

INVVY touched $31.5225 during the last trading session after $0.6225 change.Indivior PLC has volume of 2,637 shares. Since May 16, 2017 INVVY has 0.00% and is . The stock underperformed the S&P500 by 11.55%.

Indivior PLC, together with its subsidiaries, develops, makes, and sells buprenorphine prescription drugs for the treatment of opioid dependence.The firm is valued at $4.60 billion. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, overdose rescue, and schizophrenia.The P/E ratio is 78.81. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.